Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal

摘要

Acknowledgments The authors would like to thank Purnima Pathak (Novartis) for providing writing assistance in the development of this manuscript. The authors would also like to thank Colin Burke and Ronan Mahon (Health Economic Modelers; Novartis) for their modeling support. Medical writing support was funded by Novartis Pharma AG (Basel, Switzerland).